As of 2025-12-21, the Intrinsic Value of Outlook Therapeutics Inc (OTLK) is -4.89 USD. This OTLK valuation is based on the model Peter Lynch Fair Value. With the current market price of 2.01 USD, the upside of Outlook Therapeutics Inc is -343.27%.
Based on its market price of 2.01 USD and our intrinsic valuation, Outlook Therapeutics Inc (OTLK) is overvalued by 343.27%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -4.89 - -4.89 | -4.89 | -343.27% |
| P/E | (13.77) - (18.70) | (17.36) | -963.6% |
| DDM - Stable | (8.31) - (28.72) | (18.51) | -1021.0% |
| DDM - Multi | (13.45) - (36.63) | (19.73) | -1081.7% |
| Market Cap (mil) | 89.28 |
| Beta | 1.11 |
| Outstanding shares (mil) | 44.42 |
| Enterprise Value (mil) | 114.82 |
| Market risk premium | 4.60% |
| Cost of Equity | 9.65% |
| Cost of Debt | 5.00% |
| WACC | 8.51% |